The Role of Secondary Bile Acids in Intestinal Inflammation
Status:
Recruiting
Trial end date:
2050-12-01
Target enrollment:
Participant gender:
Summary
The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in
the production of molecules that impact health-are widely accepted to play a key role. A
significant proportion of IBD patients with pouches (surgically created rectums after the
diseased colon is removed) continue to have inflammation similar to their previous disease.
Only a few microbes are known to have the capability to modify primary bile acids (PBAs) made
by the liver to secondary bile acids (SBAs). SBAs are some of the most common metabolites in
the colon and play key roles in several diseases.
In this study the investigators will investigate if ursodeoxycholic acid (UDCA) may reduce
inflammatory markers and improve quality of life (as assessed by validate survey) in those
subjects with active antibiotic refractory or antibiotic dependent pouchitis.